Choroidal Neovascularization - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 65
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7531403DD1EN
Leaflet:

Download PDF Leaflet

Choroidal Neovascularization - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Choroidal Neovascularization - Pipeline Review, H2 2016’, provides an overview of the Choroidal Neovascularization pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
  • The report reviews pipeline therapeutics for Choroidal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Choroidal Neovascularization therapeutics and enlists all their major and minor projects
  • The report assesses Choroidal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Choroidal Neovascularization
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Choroidal Neovascularization Overview
Therapeutics Development
Pipeline Products for Choroidal Neovascularization - Overview
Pipeline Products for Choroidal Neovascularization - Comparative Analysis
Choroidal Neovascularization - Therapeutics under Development by Companies
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes
Choroidal Neovascularization - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Choroidal Neovascularization - Products under Development by Companies
Choroidal Neovascularization - Products under Investigation by Universities/Institutes
Choroidal Neovascularization - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd.
Formycon AG
Genentech, Inc.
Graybug Vision Inc
Mabion SA
Navigen Pharmaceuticals, Inc.
Noxxon Pharma AG
Promedior, Inc.
Choroidal Neovascularization - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Doxarubicin Pegylated - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAb-30D8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Choroidal Neovascularization - Dormant Projects
Choroidal Neovascularization - Discontinued Products
Choroidal Neovascularization - Product Development Milestones
Featured News & Press Releases
Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance
Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 65

LIST OF TABLES

Number of Products under Development for Choroidal Neovascularization, H2 2016
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Choroidal Neovascularization - Pipeline by Formycon AG, H2 2016
Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2016
Choroidal Neovascularization - Pipeline by Graybug Vision Inc, H2 2016
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2016
Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2016
Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Choroidal Neovascularization - Dormant Projects, H2 2016
Choroidal Neovascularization - Dormant Projects (Contd..1), H2 2016
Choroidal Neovascularization - Discontinued Products, H2 2016 60

LIST OF FIGURES

Number of Products under Development for Choroidal Neovascularization, H2 2016
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Choroidal Neovascularization - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: